GT200800145A - Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) de dicha formulacion - Google Patents

Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) de dicha formulacion

Info

Publication number
GT200800145A
GT200800145A GT200800145A GT200800145A GT200800145A GT 200800145 A GT200800145 A GT 200800145A GT 200800145 A GT200800145 A GT 200800145A GT 200800145 A GT200800145 A GT 200800145A GT 200800145 A GT200800145 A GT 200800145A
Authority
GT
Guatemala
Prior art keywords
solid composition
formulation
liofilized
taxane
kit
Prior art date
Application number
GT200800145A
Other languages
English (en)
Inventor
Jose Lucio Nunez
Jose Bernardo Iturraspe
Nora Adriana Moyano De Iturraspe
Antonio Osvaldo Bouzada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38134453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200800145(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200800145A publication Critical patent/GT200800145A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)

Abstract

LA PRESENTE INVENCION PERTENECE AL CAMPO DE LAS FORMULACIONES DE MEDICAMENTOS FAMRACEUTICOS ESCASAMENTE SOLUBLES EN AGUA. EN PARTICULAR SE REFIERE A FORMULACIONES DE MEDICAMENTOS ONCOLOGICOS, DONDE DICHOS MEDICAMENTOS PERTENECEN AL GRUPO DE LOS TAXANOS Y A PROCEDIMIENTOS DE OBTENCION DE LOS MISMOS. MAS PARTICULARMENTE FORMULACIONES APTAS PARA PROCESOS DE INFUSION PARENTERAL EN QUIMIOTERAPIA ONCOLOGICA PROPIA DE DOCETAXEL Y PACLITAXEL.
GT200800145A 2006-01-20 2008-07-18 Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) de dicha formulacion GT200800145A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AR20060100208A AR054215A1 (es) 2006-01-20 2006-01-20 Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit

Publications (1)

Publication Number Publication Date
GT200800145A true GT200800145A (es) 2009-07-21

Family

ID=38134453

Family Applications (2)

Application Number Title Priority Date Filing Date
GT200800146A GT200800146A (es) 2006-01-20 2008-07-18 Una formulacion farmaceutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubilizante de dicha composicion solida de taxano, y un conjunto de elementos (kit
GT200800145A GT200800145A (es) 2006-01-20 2008-07-18 Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) de dicha formulacion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GT200800146A GT200800146A (es) 2006-01-20 2008-07-18 Una formulacion farmaceutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubilizante de dicha composicion solida de taxano, y un conjunto de elementos (kit

Country Status (15)

Country Link
US (2) US20090215883A1 (es)
EP (2) EP1994925A4 (es)
JP (2) JP2009523770A (es)
AR (1) AR054215A1 (es)
AU (1) AU2007206877A1 (es)
BR (2) BRPI0706931A2 (es)
CA (2) CA2637893A1 (es)
GT (2) GT200800146A (es)
MX (2) MX2008009358A (es)
NZ (2) NZ569783A (es)
PE (2) PE20070945A1 (es)
RU (1) RU2429837C2 (es)
UY (2) UY30099A1 (es)
WO (2) WO2007082978A1 (es)
ZA (2) ZA200805704B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110209B2 (en) 2002-12-20 2012-02-07 Xeris Pharmaceuticals Inc. Intracutaneous injection
EP1583562B1 (en) 2003-01-06 2011-06-15 Angiochem Inc. Angiopep-1, related compounds, and uses thereof
BRPI0520032A2 (pt) 2005-02-18 2009-04-14 Angiochem Inc moléculas para transportar um composto através da barreira hematoencefálica
BRPI0613005A8 (pt) * 2005-07-15 2017-12-26 Angiochem Inc uso de polipeptídeos de aprotinina como veículos em conjugados farmacêuticos.
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
EP2146695A4 (en) * 2007-04-23 2010-05-19 Sun Pharmaceuticals Ind Ltd PHARMACEUTICAL COMPOSITIONS
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
MX2009013663A (es) * 2007-06-22 2010-01-27 Scidose Llc Formulacion solubilizada de docetaxel sin tween 80.
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
AR063111A1 (es) * 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
KR101478779B1 (ko) * 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
PT2279008T (pt) * 2008-04-18 2019-05-20 Angiochem Inc Composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e utilização
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
RU2531591C2 (ru) 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
CN102307904A (zh) 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
UA110196C2 (uk) * 2009-08-25 2015-12-10 Абраксіс Байосайєнс, Елелсі Комбінована терапія композиціями наночастинок таксану і інгібіторами хеджхог
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US20130058965A1 (en) * 2009-12-31 2013-03-07 Mannkind Corporation Injectable formulations for parenteral administration
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
WO2011139899A2 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
AR077384A1 (es) * 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
CA2829400C (en) 2011-03-10 2022-02-15 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
JP6117811B2 (ja) 2011-10-31 2017-04-19 ゼリス ファーマシューティカルズ インコーポレイテッド 糖尿病を処置するための製剤
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
EP2958554B1 (en) * 2013-02-19 2018-06-06 Synthon BV Stable compositions of bendamustine
EP3871709A1 (en) 2014-08-06 2021-09-01 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
EP2985038A1 (en) * 2014-08-12 2016-02-17 Azad Pharma AG Lyophilized API preparation
US20170360791A1 (en) * 2014-12-04 2017-12-21 Astex Pharmaceuticals, Inc. Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs
US20160346221A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
SG10201913945QA (en) * 2015-06-04 2020-03-30 Crititech Inc Taxane particles and their use
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
TWI715636B (zh) 2015-09-30 2021-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
JP6970683B2 (ja) 2016-04-04 2021-11-24 クリティテック・インコーポレイテッド 固形腫瘍治療のための方法
RU2708329C2 (ru) * 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
AU2018275686B2 (en) 2017-06-02 2024-02-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
WO2018227037A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
US10398646B2 (en) 2017-06-14 2019-09-03 Crititech, Inc. Methods for treating lung disorders
US11957758B2 (en) * 2017-09-07 2024-04-16 Shenzhen Salubris Pharmaceuticals Co. Ltd. Pharmaceutical composition of docetaxel conjugate and preparation method
BR112020005814A2 (pt) 2017-10-03 2020-09-24 Crititech, Inc. administração local de partículas antineoplásicas em combinação com administração sistêmica de agentes imunoterapêuticos para o tratamento de câncer
CN107496352A (zh) * 2017-10-13 2017-12-22 深圳万乐药业有限公司 一种多烯紫杉醇药物组合物及其制备方法
WO2020019363A1 (zh) * 2018-07-25 2020-01-30 比卡生物科技（广州）有限公司 一种注射用多西他赛组合物及其制备方法
AU2019410060A1 (en) 2018-12-21 2021-08-05 Modra Pharmaceuticals B.V. Cancer treatment using docetaxel by controlling peak plasma levels

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
HUP9701945A3 (en) 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
US5922754A (en) 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP4722295B2 (ja) * 1999-05-27 2011-07-13 エイカスフィアー・インコーポレーテッド 多孔性薬剤マトリクスおよびその製造方法
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
JP4874483B2 (ja) 1999-06-09 2012-02-15 ロバート イー． シーバース 超臨界流体補助ネブライゼーション及びバブル乾燥
US20010047162A1 (en) * 2000-02-17 2001-11-29 Yasumi Yugari Injection kit and injection device
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
CN1233420C (zh) * 2000-05-12 2005-12-28 株式会社三养社 通过嵌段共聚物的相分离制备聚合物胶束的方法
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
PL203300B1 (pl) * 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
US6919370B2 (en) 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US20030099674A1 (en) 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
KR100573289B1 (ko) 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
KR100508518B1 (ko) 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
US6759539B1 (en) * 2003-02-27 2004-07-06 Chaichem Pharmaceuticals International Process for isolation and purification of paclitaxel from natural sources
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CN1850056A (zh) * 2006-03-06 2006-10-25 杨典忠 多西他赛冻干粉针及其制备方法
AR063111A1 (es) * 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano

Also Published As

Publication number Publication date
ZA200805989B (en) 2009-05-27
NZ569783A (en) 2011-04-29
JP2009523770A (ja) 2009-06-25
WO2007082979A1 (es) 2007-07-26
BRPI0706932A2 (pt) 2011-04-19
UY30099A1 (es) 2008-09-02
WO2007082978A1 (es) 2007-07-26
US20090215882A1 (en) 2009-08-27
UY30100A1 (es) 2008-09-02
BRPI0706931A2 (pt) 2011-04-19
RU2008133761A (ru) 2010-02-27
PE20071243A1 (es) 2008-02-03
MX2008009357A (es) 2008-09-10
RU2429837C2 (ru) 2011-09-27
CA2638034A1 (en) 2007-07-26
GT200800146A (es) 2008-12-15
EP1982699A1 (en) 2008-10-22
WO2007082978B1 (es) 2007-09-07
MX2008009358A (es) 2008-09-10
NZ569968A (en) 2011-07-29
AU2007206876A1 (en) 2007-07-26
AR054215A1 (es) 2007-06-13
EP1994925A4 (en) 2013-01-23
CA2637893A1 (en) 2007-07-26
PE20070945A1 (es) 2007-10-07
AU2007206877A1 (en) 2007-07-26
ZA200805704B (en) 2009-11-25
JP2009523771A (ja) 2009-06-25
EP1994925A1 (en) 2008-11-26
US20090215883A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
GT200800145A (es) Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) de dicha formulacion
CL2009001766A1 (es) Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica.
UY33775A (es) Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
CO6290656A2 (es) Derivados heterociclicos de urea y metodos de uso de los mismos -211
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
CL2014000511A1 (es) Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer.
CL2012003421A1 (es) Compuestos derivados de 3-amino-n-(4-carbamoilpiridin-3-il)(aril/heteroaril)-2-carboxamida; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad del snc, oncologica, entre otras. pct fase nacional
CU20080052A7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CO6341565A2 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
UY30444A1 (es) Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
UY31456A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
CL2007003514A1 (es) Compuestos derivados de quinolina; procedimiento de preparacion de dichos compuestos; combinacion farmaceutica; y uso de los compuestos para preparar un medicamento para tratar una infeccion bacteriana.
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
UY33075A (es) Derivados de ciclohexano y usos de los mismos
CL2013003161A1 (es) Composicion farmaceutica en forma de microgranulos de disolucion rapida para administracion vaginal que comprende a) un farmaco vaginalmente activo, b) un excipiente polimerico, c) un alcohol de azucar, sacarido o una mezcla de los mismos; procedimiento de preparacion.
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos